Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Total Liabilities: 2017-2025

Historic Total Liabilities for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to $31.0 million.

  • Dianthus Therapeutics' Total Liabilities rose 89.55% to $31.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 million, marking a year-over-year increase of 89.55%. This contributed to the annual value of $21.5 million for FY2024, which is 104.38% up from last year.
  • As of Q3 2025, Dianthus Therapeutics' Total Liabilities stood at $31.0 million, which was up 34.76% from $23.0 million recorded in Q2 2025.
  • Dianthus Therapeutics' Total Liabilities' 5-year high stood at $43.2 million during Q1 2022, with a 5-year trough of $4.0 million in Q2 2023.
  • Its 3-year average for Total Liabilities is $15.2 million, with a median of $14.1 million in 2023.
  • Per our database at Business Quant, Dianthus Therapeutics' Total Liabilities tumbled by 89.77% in 2023 and then soared by 166.26% in 2024.
  • Dianthus Therapeutics' Total Liabilities (Quarterly) stood at $9.5 million in 2022, then increased by 11.43% to $10.5 million in 2023, then soared by 104.38% to $21.5 million in 2024, then soared by 89.55% to $31.0 million in 2025.
  • Its Total Liabilities stands at $31.0 million for Q3 2025, versus $23.0 million for Q2 2025 and $20.0 million for Q1 2025.